DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 8,383,155 B2 Bar-Shalom Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 8,383,155 B2 Bar-Shalom Et Al US008383155B2 (12) United States Patent (10) Patent No.: US 8,383,155 B2 Bar-Shalom et al. (45) Date of Patent: Feb. 26, 2013 (54) SWELLABLE DOSAGE FORM COMPRISING FOREIGN PATENT DOCUMENTS GELLAN GUMI EP O272220 6, 1993 EP 1371 360 B1 12/2003 JP 11-187827 7, 1999 (75) Inventors: Daniel Bar-Shalom, Kokkedal (DK); JP 2004-97114 4/2004 Lillian Slot, Virum (DK); Gina Fischer, WO WO92f1 1084 7, 1992 Vaerlose (DK); Pernille Hoyrup WO WO97/38679 A2 10, 1997 Hemmingsen, Bagsvaerd (DK) WO WO 98.23292 A1 6, 1998 WO WO99/62498 A1 12/1999 WO WOO1,76610 10, 2001 (73) Assignee: Egalet A/S, Vaerlose (DK) WO WOO2,46571 A2 6, 2002 WO WO O2/49571 A2 6, 2002 (*) Notice: Subject to any disclaimer, the term of this WO WO 03/043638 A1 5, 2003 patent is extended or adjusted under 35 WO WO 2004/096906 11, 2004 WO WO 2004/096906 A1 11, 2004 U.S.C. 154(b) by 0 days. WO WO 2005/007074 1, 2005 (21) Appl. No.: 13/212,679 WO WO 2005/007074 A 1, 2005 OTHER PUBLICATIONS (22) Filed: Aug. 18, 2011 JECFA, “Gellan Gum.” FNP 52 Addendum 4 (1996). (65) Prior Publication Data JECFA, “Talc.” FNP 52 Addendum 1 (1992). Alterna LLC, “ElixSure, Allergy Formula', description and label US 2012/OO39969 A1 Feb. 16, 2012 directions, online (Feb. 6, 2007). Hagerström, H., “Polymer gels as pharmaceutical dosage forms'. comprehensive Summaries of Uppsala dissertations from the faculty Related U.S. Application Data of pharmacy, vol. 293 Uppsala (2003). Lin, “Gellan Gum', U.S. Food and Drug Administration, www. (62) Division of application No. 1 1/596,123, filed as inchem.org, online (Jan. 17, 2005). application No. PCT/DK2005/000317 on May 11, Miyazaki, S., et al., “In situ-gelling gellan formulations as vehicles 2005. for oral drug delivery”. J. Control Release, vol. 60, pp. 287-295 (1999). (30) Foreign Application Priority Data Rowe, Raymond C. et al., “Handbook of Pharmaceutical Excipients'. Pharmaceutical Press, Fourth Edition, 2003, pp. 257 May 11, 2004 (DK) ................................. 2004 OO755 258. “Gellan Gum Wins IFT's Food Technology Industrial Achievement (51) Int. Cl. Award.” Food Technology, Institute of Food Technologists, vol. 47. A6 IK 8/02 (2006.01) No. 9, Sep. 1, 1993, pp. 94-96. A6 IK9/48 (2006.01) Monsanto, “Kelcogel Gellan Gum.” Kelcogel, 1998. A6 IK3I/546 (2006.01) (Continued) A6 IK3I/44 (2006.01) A 6LX3L/295 (2006.01) A 6LX3L/75 (2006.01) Primary Examiner – Walter Webb A6 IK 8/00 (2006.01) (74) Attorney, Agent, or Firm — Foley & Lardner LLP A6 IK3I/67 (2006.01) A6 IK9/00 (2006.01) (57) ABSTRACT A6 IK3I/92 (2006.01) A61O I/00 (2006.01) A novel dosage form. The dosage form is presented in par A61O II/00 (2006.01) ticulate form and before oral ingestion the particulate mate A6IP 43/00 (2006.01) rial is subjected to an aqueous medium, whereby it is con A6IP 29/00 (2006.01) Verted to a semi-solid form by Swelling or gelling of one or (52) U.S. Cl. ........................................ 424/485; 426/573 more of the components, especially of a gellan gum, of the (58) Field of Classification Search ................... 424/484 particulate matter. The invention also relates to a vehicle for See application file for complete search history. oral administration of one or more active Substances, the vehicle comprising a gellan gum arranged in a configuration (56) References Cited allowing optimal water diffusion so that upon addition of a predetermined amount of an aqueous medium, without the U.S. PATENT DOCUMENTS necessity of applying shear forces or other mixing forces, 4,590,075 A 5, 1986 Wei et al. within a time period of 5 minutes or less swells and/or gels 4,824,681 A 4, 1989 Schobel et al. and the texture of the swelled vehicle being similar to that of 4,882,169 A 11, 1989 Ventouras a soft pudding and having a viscosity of at least about 10,000 4,994.260 A 2f1991 Kallstrand et al. 5,126,151 A 6, 1992 Boder et al. cps as measured by a Brookfield Viscometer with a #4 LV 6,102.254. A 8, 2000 ROSS spindle at 6 rpm and at 20-25°C. In one embodiment of the 6,395,298 B1 5/2002 Flanagan et al. invention, the particulate matter can be molded into a desired 6,488.962 B1 12/2002 Berner et al. shape or pressed onto a dispensing unit such as a spoon. 6,709,678 B2 3, 2004 Gruber 2003/0232082 A1 12, 2003 Li et al. 2004/O247675 A1 12, 2004 Gruber et al. 22 Claims, 10 Drawing Sheets US 8,383,155 B2 Page 2 OTHER PUBLICATIONS Office Action issued on Nov. 24, 2010 by the Examiner in U.S. Appl. Bar-Shalom et al., “Opportunities and obstacles in Pediatric Oral No. 1 1/596,123 (US 2008/02991.99). Controlled Release Dosage Forms.” Parvulet Poster, Online, Oct. 28. Office Action issued on Aug. 17, 2010 by the Examiner in U.S. Appl. 2004. No. 1 1/596,123 (US 2008/02991.99). Office Action issued on May 11, 2011 by the Examiner in U.S. Appl. Office Action issued on Oct. 17, 2011 by the Examiner in U.S. Appl. No. 1 1/596,123 (US 2008/02991.99). No. 1 1/596,123 (US 2008/02991.99). U.S. Patent Feb. 26, 2013 Sheet 1 of 10 US 8,383,155 B2 U.S. Patent Feb. 26, 2013 Sheet 2 of 10 US 8,383,155 B2 Dissolution of 200 mg Paracetamol parvulet -- 61%. Coated Paracetamol -s-200 mg Paracetamol parvulet -a-200 mg Paracetamol. parvulet e -X-200 mg Paracetamol parvulet -- 200 mg Paracetamol parvulet -e-200 mg Paracetamol parvulet |- O 5 1 O 15 20 25 30 35 4O 45 5O 55 time min Fig. 2 U.S. Patent Feb. 26, 2013 Sheet 3 of 10 US 8,383,155 B2 Figure 3 U.S. Patent Feb. 26, 2013 Sheet 4 of 10 US 8,383,155 B2 Figure 4 U.S. Patent Feb. 26, 2013 Sheet 5 of 10 US 8,383,155 B2 Figure 5 U.S. Patent Feb. 26, 2013 Sheet 6 of 10 US 8,383,155 B2 Figure 6 U.S. Patent Feb. 26, 2013 Sheet 7 of 10 US 8,383,155 B2 Figure 7 U.S. Patent Feb. 26, 2013 Sheet 8 of 10 US 8,383,155 B2 Figure 8 U.S. Patent Feb. 26, 2013 Sheet 9 of 10 US 8,383,155 B2 -- Wesse 1 w-r- Wessel 2 |-- Wessel 3 reham vesse 4 mer Wesses wam Vesses O y- - mym wn -M -- O 1. 2O 30 4. 50 s 70 Time ?min) - Fig. 9 U.S. Patent Feb. 26, 2013 Sheet 10 of 10 US 8,383,155 B2 CL (O) () | \Ll (1a) - N3-27 (1b) CIT O) (2) -- Ssey (2e) OL (O) (c) / N321 Fig. 10 US 8,383,155 B2 1. 2 SWELLABLE DOSAGE FORM COMPRISING then be formulated into tablets or capsules meant to be swal GELLAN GUMI lowed whole. Those tablets and capsules as Such are inappro priate for patients with Swallowing difficulties. Patients (or FIELD OF THE INVENTION they providers in the case of children) are often instructed to open the capsules (or crush the tablets) and to sprinkle the The present application relates to a novel dosage form. The powder on syrup or pudding or applesauce or similar and then dosage form is presented in particulate form and before oral administered. This approach has limitations. The carrier ingestion the particulate material is subjected to an aqueous (syrup, pudding, applesauce) is not a well defined entity and medium, whereby it is converted to a semi-solid form by different carriers might interact differently with the multi Swelling or gelling of one or more of the components, espe 10 particles and/or drug and thereby compromise the treatment. cially of a gellan gum, of the particulate matter. The invention Also, children might object to the grittiness in the material. also relates to a vehicle for oral administration of one or more Syrups do not necessarily resemble types of food or bever active Substances, the vehicle comprising a gellan gum ages that children are used to consume. arranged in a configuration allowing optimal water diffusion Alternatively the powder can be formulated into efferves so that upon addition of a predetermined amount of an aque 15 cent granules or tablets. These granules or tablets are intended ous medium, without the necessity of applying shear forces or to be dissolved in an aqueous liquid requiring the provision of other mixing forces, within a time period of 5 minutes or less a glass of liquid and a waiting period Sufficient to allow the swells and/or gels and the texture of the swelled vehicle being tablet to completely dissolve and the resulting Volume might similar to that of a soft pudding and having a viscosity of at be considerable. Often, these dosage forms leave an objec least about 10,000 cps as measured by a Brookfield Viscom tionable deposit in the glass, which may represent a non eter with a #4 LV spindle at 6 rpm and at 20-25°C. ingested part of the drug. Effervescent formulations are, in In one embodiment of the invention, the particulate matter general more appropriate for adults although some commer can be molded into a desired shape or pressed onto a dispens cial vitamin preparations for children use this approach.
Load more

Recommended publications
  • Derivatives of Clavulanic Acid, Process for Their Preparation And
    Europaisches Patentamt © ê European Patent Office © Publication number: 0 003 254 Office européen des brevets Bl © EUROPEAN PATENT SPECIFICATION (45) Date of publication of patent spécification: 28.03.84 © Int. ci.3: C 07 D 498/04, A 61 K 31/42, @ Application number: 78300762.8 A 61 K 31/43, @ Date offiling: 07.12.78 A 61 K 31/545 //(C07D498/04, 263/00, 205/00), (A6 1 K3 1 /43, 3 1/42), (A61K3 1/545, 31/42) (54) Derivatives of clavulanic acid, process for their préparation and compositions containing them. (§) Priority: 26.01 .78 GB 312978 @ Proprietor: BEECHAM GROUP PLC Beecham House Great West Road Brentford Middlesex (GB) (43) Date of publication of application: 08.08.79 Bulletin 79/1 6 @ Inventor: Gasson, Brian Charles 9, Clarence Walk (45) Publication of the grant of the patent: Redhill Surrey (GB) 28.03.84 Bulletin 84/13 © Représentative: Hesketh, Alan, Dr. et al, (84) Designated Contracting States: European Patent Attorney Beecham BE CH DEFRGBITNL Pharmaceuticals Great Burgh Yew Tree Bottom Road Epsom, Surrey, KT18 5XQ (GB) (56) Références cited: BE - A - 847 046 The file contains technical information submitted after the application was filed and not included in this spécification Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid.
    [Show full text]
  • Multiresidue Determination of Sarafloxacin, Difloxacin, Norfloxacin, and Pefloxacin in Fish Using an Enzyme-Linked Immunosorbent Assay
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Available online at www.sciencedirect.com Procedia Environmental Sciences 8 (2011) 301 – 306 ICESB 2011: 25-26 November 2011, Maldives Multiresidue Determination of Sarafloxacin, Difloxacin, Norfloxacin, and Pefloxacin in Fish using an Enzyme-Linked Immunosorbent Assay ∗ Jiang Jinqing a, Zhang Haitang a, Wang Ziliang a,b aCollege of Animal Science, Henan Institute of Science and Technology, Xinxiang, 453003, China bHenan Provincial Laboratory for Key Disciplines of Animal Virosis Control and Residues Supervison, Xinxiang 453003, China Abstract An indirect competitive ELISA (icELISA) method for multiresidue determination of Fluoroquinolones (FQs) residues in fish samples has been developed. For this purpose, Sarafloxacin (SAR) was employed to synthesize the immunogen and coating antigen through EDC conjugation method, and cell fusion technology was used to produce anti-SAR monoclonal antiobdy. Based on the square matrix titration, an icELISA method was established. The dynamic range for Sarafloxacin in assay buffer was from 0.004 to 18 ng/mL, with LOD and IC50 value of 0.002 ng/mL and 0.32 ng/mL, respectively. After optimization, the physiological pH (7.4) was selected for the immunoassays, and this assay could tolerate up to 10% acetonitrile. The results of this assay showed a high cross- reactivity to Difloxacin (85.5%), Norfloxacin (61.7%), and Pefloxacin (34.8%). Under the 10-fold dilution in authentic fish samples, the regression curve equations for Sarafloxacin, Difloxacin, Norfloxacin and Pefloxacin were y = 1.0114x - 0.4003, R2= 0.9901; y = 0.9782x + 0.2754, R2= 0.9807; y = 0.9892x +0.0489, R2= 0.9843; and y = 0.9797x +0.8017, R2= 0.9844, respectively.
    [Show full text]
  • The Oral Pheneticillin Absorption Test: an Accurate Method to Identify Patients with Inadequate Oral Pheneticillin Absorption
    antibiotics Brief Report The Oral Pheneticillin Absorption Test: An Accurate Method to Identify Patients with Inadequate Oral Pheneticillin Absorption Anneke C. Dijkmans 1,*, Dinemarie M. Kweekel 2, Jaap T. van Dissel 3, Michiel J. van Esdonk 1 , Ingrid M. C. Kamerling 1 and Jacobus Burggraaf 1 1 Centre for Human Drug Research (CHDR), 2333 CL Leiden, The Netherlands 2 Department of Clinical Pharmacy, Leiden University Medical Center (LUMC), 2333 ZA LeidenLeiden, The Netherlands 3 Department of Infectious Diseases, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands * Correspondence: [email protected] Received: 9 July 2019; Accepted: 8 August 2019; Published: 15 August 2019 Abstract: Severe streptococcal infections are commonly treated with intravenous followed by oral penicillin (pheneticillin) therapy. However, switching from iv to oral therapy is complicated by the variability in oral pheneticillin absorption. We employed an Oral Absorption Test (OAT) for pheneticillin to identify patients in whom oral pheneticillin absorption is poor. Out of 84 patients 30 patients (36%) were identified as insufficient absorbers. Treatment failure due to pheneticillin malabsorption can be avoided by performing an OAT, and these patients should be treated by another antibiotic, which is known to be absorbed well. Keywords: penicillin; oral; pheneticillin; streptococcal 1. Background In the Netherlands, patients with severe streptococcal infections are effectively treated with narrow-spectrum antibiotics, most frequently with initial intravenous (iv) penicillin G followed by oral maintenance therapy, usually with pheneticillin. The advantages of this treatment approach are the bactericidal activity of penicillin, the low costs, the possibility to switch to an oral antibiotic as soon as possible, and the lower risk of introducing resistance associated with narrow-spectrum antibiotics.
    [Show full text]
  • Multi-Residual Quantitative Analytical Method for Antibiotics in Sea Food by LC/MS/MS
    PO-CON1742E Multi-residual quantitative analytical method for antibiotics in sea food by LC/MS/MS ASMS 2017 TP 198 Anant Lohar, Shailendra Rane, Ashutosh Shelar, Shailesh Damale, Rashi Kochhar, Purushottam Sutar, Deepti Bhandarkar, Ajit Datar, Pratap Rasam and Jitendra Kelkar Shimadzu Analytical (India) Pvt. Ltd., 1 A/B, Rushabh Chambers, Makwana Road, Marol, Andheri (E), Mumbai-400059, Maharashtra, India. Multi-residual quantitative analytical method for antibiotics in sea food by LC/MS/MS Introduction Antibiotics are widely used in agriculture as growth LC/MS/MS method has been developed for quantitation of enhancers, disease treatment and control in animal feeding multi-residual antibiotics (Table 1) from sea food sample operations. Concerns for increased antibiotic resistance of using LCMS-8040, a triple quadrupole mass spectrometer microorganisms have prompted research into the from Shimadzu Corporation, Japan. Simultaneous analysis environmental occurrence of these compounds. of multi-residual antibiotics often exhibit peak shape Assessment of the environmental occurrence of antibiotics distortion owing to their different chemical nature. To depends on development of sensitive and selective overcome this, autosampler pre-treatment feature was analytical methods based on new instrumental used [1]. technologies. Table 1. List of antibiotics Sr.No. Name of group Name of compound Number of compounds Flumequine, Oxolinic Acid, Ciprofloxacin, Danofloxacin, Difloxacin.HCl, 1 Fluoroquinolones 8 Enrofloxacin, Sarafloxacin HCl Trihydrate,
    [Show full text]
  • AMEG Categorisation of Antibiotics
    12 December 2019 EMA/CVMP/CHMP/682198/2017 Committee for Medicinal Products for Veterinary use (CVMP) Committee for Medicinal Products for Human Use (CHMP) Categorisation of antibiotics in the European Union Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 29 October 2018 Adopted by the CVMP for release for consultation 24 January 2019 Adopted by the CHMP for release for consultation 31 January 2019 Start of public consultation 5 February 2019 End of consultation (deadline for comments) 30 April 2019 Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 19 November 2019 Adopted by the CVMP 5 December 2019 Adopted by the CHMP 12 December 2019 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Categorisation of antibiotics in the European Union Table of Contents 1. Summary assessment and recommendations .......................................... 3 2. Introduction ............................................................................................ 7 2.1. Background ........................................................................................................
    [Show full text]
  • Consideration of Antibacterial Medicines As Part Of
    Consideration of antibacterial medicines as part of the revisions to 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) Section 6.2 Antibacterials including Access, Watch and Reserve Lists of antibiotics This summary has been prepared by the Health Technologies and Pharmaceuticals (HTP) programme at the WHO Regional Office for Europe. It is intended to communicate changes to the 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) to national counterparts involved in the evidence-based selection of medicines for inclusion in national essential medicines lists (NEMLs), lists of medicines for inclusion in reimbursement programs, and medicine formularies for use in primary, secondary and tertiary care. This document does not replace the full report of the WHO Expert Committee on Selection and Use of Essential Medicines (see The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization; 2019 (WHO Technical Report Series, No. 1021). Licence: CC BY-NC-SA 3.0 IGO: https://apps.who.int/iris/bitstream/handle/10665/330668/9789241210300-eng.pdf?ua=1) and Corrigenda (March 2020) – TRS1021 (https://www.who.int/medicines/publications/essentialmedicines/TRS1021_corrigenda_March2020. pdf?ua=1). Executive summary of the report: https://apps.who.int/iris/bitstream/handle/10665/325773/WHO- MVP-EMP-IAU-2019.05-eng.pdf?ua=1.
    [Show full text]
  • The Current Case of Quinolones: Synthetic Approaches and Antibacterial Activity
    molecules Review The Current Case of Quinolones: Synthetic Approaches and Antibacterial Activity Abdul Naeem 1, Syed Lal Badshah 1,2,*, Mairman Muska 1, Nasir Ahmad 2 and Khalid Khan 2 1 National Center of Excellence in Physical Chemistry, University of Peshawar, Peshawar, Khyber Pukhtoonkhwa 25120, Pakistan; [email protected] (A.N.); [email protected] (M.M.) 2 Department of Chemistry, Islamia College University Peshawar, Peshawar, Khyber Pukhtoonkhwa 25120, Pakistan; [email protected] (N.A.); [email protected] (K.K.) * Correspondence: [email protected]; Tel.: +92-331-931-6672 Academic Editor: Peter J. Rutledge Received: 23 December 2015 ; Accepted: 15 February 2016 ; Published: 28 March 2016 Abstract: Quinolones are broad-spectrum synthetic antibacterial drugs first obtained during the synthesis of chloroquine. Nalidixic acid, the prototype of quinolones, first became available for clinical consumption in 1962 and was used mainly for urinary tract infections caused by Escherichia coli and other pathogenic Gram-negative bacteria. Recently, significant work has been carried out to synthesize novel quinolone analogues with enhanced activity and potential usage for the treatment of different bacterial diseases. These novel analogues are made by substitution at different sites—the variation at the C-6 and C-8 positions gives more effective drugs. Substitution of a fluorine atom at the C-6 position produces fluroquinolones, which account for a large proportion of the quinolones in clinical use. Among others, substitution of piperazine or methylpiperazine, pyrrolidinyl and piperidinyl rings also yields effective analogues. A total of twenty six analogues are reported in this review. The targets of quinolones are two bacterial enzymes of the class II topoisomerase family, namely gyrase and topoisomerase IV.
    [Show full text]
  • Belgian Veterinary Surveillance of Antibacterial Consumption National
    Belgian Veterinary Surveillance of Antibacterial Consumption National consumption report 2020 Publication : 22 June 2021 1 SUMMARY This annual BelVet-SAC report is now published for the 12th time and describes the antimicrobial use (AMU) in animals in Belgium in 2020 and the evolution since 2011. For the third year this report combines sales data (collected at the level of the wholesalers-distributors and the compound feed producers) and usage data (collected at farm level). This allows to dig deeper into AMU at species and farm level in Belgium. With a consumption of 87,6 mg antibacterial compounds/kg biomass an increase of +0.2% is seen in 2020 in comparison to 2019. The increase seen in 2020 is spread over both pharmaceuticals (+0.2%) and antibacterial premixes (+4.0%). This unfortunately marks the end of a successful reduction in antibacterial product sales that was seen over the last 6 years resulting in a cumulative reduction of -40,2% since 2011. The gap seen in the coverage of the sales data with the Sanitel-Med collected usage data increased substantially compared to 2019, meaning continuous efforts need to be taken to ensure completeness of the collected usage data. When looking at the evolution in the number of treatment days (BD100) at the species level, as calculated from the SANITEL- MED use data, use increased in poultry (+5,0%) and veal calves (+1,9%), while it decreased in pigs (-3,1%). However, the numerator data for this indicator remain to be updated for 2020, potentially influencing the reliability of the result.
    [Show full text]
  • AMR in Fisheries and Aquaculture Products
    AMR in fisheries and aquaculture products Products, Trade and Marketing Branch Fisheries and Aquaculture Department Food and Agriculture Organization of the United Nations What accelerates the emergence and spread of AMR? Poor infection control, inadequate sanitary conditions and misused of antimicrobials among others Role of modifiable drivers for antimicrobial resistance: a conceptual framework (Alison H Holmes, 2015) EU FISH AND CRUSTACEANS PRODUCT ALERTS Hazard Category 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Microbiological 52 75 11 17 24 68 70 65 52 31 58 38 38 Chemical and 118 177 203 221 108 135 123 149 134 170 221 128 133 residues Histamine 39 22 29 44 39 51 35 32 44 53 40 33 42 Toxins 0 0 0 0 0 0 0 0 0 0 0 2 4 Parasitic infestation 51 21 15 27 38 70 85 96 54 11 18 11 22 Others 33 14 29 35 46 120 123 137 127 73 43 83 88 TOTAL ALERTS 293 309 287 344 255 444 436 479 411 338 380 295 327 Hazard Category 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Microbiological 51 25 6 4 8 8 13 7 9 3 6 10 15 Chemical and 103 128 122 108 111 145 43 40 31 24 57 31 46 residues Others 5 1 10 9 3 23 22 29 20 26 14 17 8 Biotoxins 0 2 1 0 0 0 0 0 0 0 0 0 0 TOTAL ALERTS 159 156 139 121 122 176 78 76 60 53 77 58 69 Source: Rapid Alert System for Food and Feed, European Commission IMPORT REFUSALS DUE TO CHEMICAL HAZARDS IN EU DIOXINS 2% 35 ADDITIVES 4% 30 25 BENZO(a)PYRENE 6% 20 OTHER CHEMICAL HAZARDS 8% 15 10 5 ANTIMICROBIALS 18% 0 HEAVY METALS 62% 2010 2011 2012 2013 2014 2015 2016 JAPAN FISHERY PRODUCTS DETENTION
    [Show full text]
  • Multi-Class Confirmatory Method for Analyzing Trace Levels of Tetracyline
    RAPID COMMUNICATIONS IN MASS SPECTROMETRY Rapid Commun. Mass Spectrom. 2007; 21: 3487–3496 Published online in Wiley InterScience (www.interscience.wiley.com) DOI: 10.1002/rcm.3236 Multi-class confirmatory method for analyzing trace levels of tetracyline and quinolone antibiotics in pig tissues by ultra-performance liquid chromatography coupled with tandem mass spectrometry Bing Shao1,4*, Xiaofei Jia1, Yongning Wu2, Jianying Hu3, Xiaoming Tu1 and Jing Zhang1 1Beijing Center for Disease Control and Prevention, Beijing 100013, China 2Institute of Nutrition and Food Safety, China Center for Disease Control and Prevention, Beijing 100085, China 3College of Environmental Science, Peking University, Beijing 100871, China 4School of Public Health and Family Medicine, Capital Medical University, Beijing 100089, China Received 8 June 2007; Revised 26 August 2007; Accepted 27 August 2007 An ultra-performance liquid chromatography coupled with tandem mass spectrometry (UPLC/MS/ MS) method was developed to screen and confirm multi-class veterinary drug residues in pig tissues including pig kidney, liver and meat. Twenty-one drugs of two different classes including seven tetracyclines and four types of quinolones (quinoline, naphthyridine, pyridopyrimidine and cino- line) were determined simultaneously in a single run. The homogenized sample tissues were extracted with EDTA–McIlvaine buffer solution and further purified using a polymer-based Oasis TM HLB solid-phase extraction (SPE) cartridge. An ACQUITY UPLC BEH C18 column was used to separate the analytes followed by tandem mass spectrometry using an electrospray ionization source. MS data acquisition was performed in the positive ion multiple reaction monitoring mode, selecting two ion transitions for each target compound. Recovery studies were performed at different fortification levels.
    [Show full text]
  • EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use
    Ref. Ares(2019)6843167 - 05/11/2019 31 October 2019 EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use Advice on implementing measures under Article 37(4) of Regulation (EU) 2019/6 on veterinary medicinal products – Criteria for the designation of antimicrobials to be reserved for treatment of certain infections in humans Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Introduction On 6 February 2019, the European Commission sent a request to the European Medicines Agency (EMA) for a report on the criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans in order to preserve the efficacy of those antimicrobials. The Agency was requested to provide a report by 31 October 2019 containing recommendations to the Commission as to which criteria should be used to determine those antimicrobials to be reserved for treatment of certain infections in humans (this is also referred to as ‘criteria for designating antimicrobials for human use’, ‘restricting antimicrobials to human use’, or ‘reserved for human use only’). The Committee for Medicinal Products for Veterinary Use (CVMP) formed an expert group to prepare the scientific report. The group was composed of seven experts selected from the European network of experts, on the basis of recommendations from the national competent authorities, one expert nominated from European Food Safety Authority (EFSA), one expert nominated by European Centre for Disease Prevention and Control (ECDC), one expert with expertise on human infectious diseases, and two Agency staff members with expertise on development of antimicrobial resistance .
    [Show full text]
  • Development of an Antibiotic Policy in a Zoological Medicine Service and Approach to Antibiotic Dosing Using Minimum Inhibitory Concentration Data Stephen J
    Development of an Antibiotic Policy in a Zoological Medicine Service and Approach to Antibiotic Dosing Using Minimum Inhibitory Concentration Data Stephen J. Divers, BVetMed, DZooMed, DipECZM (Herpetology), DipECZM (Zoo Health Management), Dipl ACZM, FRCVS, Izidora Sladakovic, BVSc (Hons I), MVS, Jörg Mayer, DVM, MS, DipECZM (Exotic Mammals), Dipl ACZM, DABVP (Exotic Companion Mammal Practice), Susan Sanchez, BSc, MSc, PhD, FRSB Session #2101 Affiliation: From The Department of Small Animal Medicine and Surgery (Divers, Sladakovic, Mayer) and Athens Veterinary Diagnostic Laboratory (Sanchez), College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA. Abstract: Antimicrobial resistance is a major veterinary concern, and yet despite widespread literature and policies advocating appropriate antibiotic stewardship in domesticated veterinary medicine, there appears to have been very little progress in zoological medicine, especially companion exotic practice. An example of an antibiotic policy for a zoological medicine service is described, along with general advice on appropriate antibiotic use, including minimum inhibitory concentration (MIC)-determined drug dosing. Introduction Antimicrobial resistance (AMR) is a global veterinary and public health challenge, which has accelerated by the overuse of antibiotics worldwide. Increased antimicrobial resistance is the cause of severe infections, complica- tions, longer hospital stays and increased mortality. Overprescribing of antibiotics is associated with an increased risk
    [Show full text]